Oliver Seifert

1.0k total citations
32 papers, 796 citations indexed

About

Oliver Seifert is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Oliver Seifert has authored 32 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 18 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Oncology. Recurrent topics in Oliver Seifert's work include Monoclonal and Polyclonal Antibodies Research (18 papers), Glycosylation and Glycoproteins Research (10 papers) and Cell death mechanisms and regulation (8 papers). Oliver Seifert is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), Glycosylation and Glycoproteins Research (10 papers) and Cell death mechanisms and regulation (8 papers). Oliver Seifert collaborates with scholars based in Germany, Ukraine and United Kingdom. Oliver Seifert's co-authors include Roland E. Kontermann, Klaus Pfizenmaier, Meike Hutt, Fabian Richter, Martin Siegemund, Felix Unverdorben, Nicolas Fischer, Pauline Malinge, Jens Kurreck and Tatjana Schütze and has published in prestigious journals such as Nucleic Acids Research, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Oliver Seifert

32 papers receiving 784 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oliver Seifert Germany 17 473 258 249 210 90 32 796
Mahdi Habibi‐Anbouhi Iran 19 589 1.2× 452 1.8× 181 0.7× 302 1.4× 73 0.8× 68 975
Patrick Bühler Germany 15 233 0.5× 378 1.5× 227 0.9× 211 1.0× 53 0.6× 21 709
Yanchun Meng China 15 298 0.6× 193 0.7× 262 1.1× 88 0.4× 133 1.5× 41 655
Elliot C. Woods United States 10 885 1.9× 184 0.7× 186 0.7× 467 2.2× 51 0.6× 14 1.3k
Patricia Álamo Spain 22 610 1.3× 150 0.6× 245 1.0× 295 1.4× 224 2.5× 43 1.0k
Andrey S. Dobroff United States 21 761 1.6× 134 0.5× 236 0.9× 270 1.3× 105 1.2× 35 1.2k
Johan Nilvebrant Sweden 16 420 0.9× 425 1.6× 231 0.9× 93 0.4× 44 0.5× 43 694
Marta M. Kijanka Netherlands 7 389 0.8× 356 1.4× 148 0.6× 140 0.7× 53 0.6× 8 687
Martin Hülsmeyer Germany 14 402 0.8× 220 0.9× 125 0.5× 468 2.2× 49 0.5× 18 1.1k

Countries citing papers authored by Oliver Seifert

Since Specialization
Citations

This map shows the geographic impact of Oliver Seifert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Seifert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Seifert more than expected).

Fields of papers citing papers by Oliver Seifert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Seifert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Seifert. The network helps show where Oliver Seifert may publish in the future.

Co-authorship network of co-authors of Oliver Seifert

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Seifert. A scholar is included among the top collaborators of Oliver Seifert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Seifert. Oliver Seifert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gericke, Birthe, et al.. (2025). Immunoliposomes – a new therapeutic option to treat SynGAP1-associated epilepsy. European Journal of Pharmaceutics and Biopharmaceutics. 214. 114799–114799. 1 indexed citations
2.
Abassi, Leila, Federico Bertoglio, Thomas Schirrmann, et al.. (2023). Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses. 15(11). 2153–2153. 2 indexed citations
3.
Olayioye, Monilola A., et al.. (2021). A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3. mAbs. 13(1). 1902034–1902034. 8 indexed citations
4.
Seifert, Oliver, et al.. (2021). Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. Journal for ImmunoTherapy of Cancer. 9(11). e003616–e003616. 5 indexed citations
5.
Seifert, Oliver, et al.. (2021). A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Scientific Reports. 11(1). 13880–13880. 6 indexed citations
6.
Lieb, Wolfgang, et al.. (2020). Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3. Molecular Cancer Therapeutics. 19(7). 1474–1485. 35 indexed citations
7.
Fabre, Myriam, Cristina Suárez Ferrer, Bruno Bockorny, et al.. (2020). OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clinical Cancer Research. 26(13). 3420–3430. 74 indexed citations
8.
Vetma, Vesna, Cristiano Guttà, Nathalie Peters, et al.. (2020). Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism. Cell Death and Differentiation. 27(8). 2417–2432. 15 indexed citations
9.
Richter, Fabian, Oliver Seifert, Andreas Herrmann, Klaus Pfizenmaier, & Roland E. Kontermann. (2019). Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. mAbs. 11(4). 653–665. 15 indexed citations
10.
Richter, Fabian, Kirstin A. Zettlitz, Oliver Seifert, et al.. (2018). Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. mAbs. 11(1). 166–177. 17 indexed citations
11.
Siegemund, Martin, F Schneider, Meike Hutt, et al.. (2018). IgG-single-chain TRAIL fusion proteins for tumour therapy. Scientific Reports. 8(1). 7808–7808. 23 indexed citations
12.
Hutt, Meike, Oliver Seifert, Martin Siegemund, et al.. (2017). Superior Properties of Fc-comprising scTRAIL Fusion Proteins. Molecular Cancer Therapeutics. 16(12). 2792–2802. 34 indexed citations
13.
Seifert, Oliver, Meike Hutt, Simone Schmid, et al.. (2017). Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. mAbs. 9(5). 831–843. 19 indexed citations
14.
Siegemund, Martin, Oliver Seifert, Sabine Münkel, et al.. (2016). An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. mAbs. 8(5). 879–891. 31 indexed citations
15.
Unverdorben, Felix, Fabian Richter, Meike Hutt, et al.. (2015). Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. mAbs. 8(1). 120–128. 81 indexed citations
16.
Kang, Biao, Susanne Schöttler, Oliver Seifert, et al.. (2015). Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials. 49. 125–134. 54 indexed citations
17.
Seifert, Oliver, Marcus Menger, Tatjana Schütze, et al.. (2014). Identification and characterization of RNA guanine-quadruplex binding proteins. Nucleic Acids Research. 42(10). 6630–6644. 106 indexed citations
18.
Siegemund, Martin, Fabian Richter, Oliver Seifert, Felix Unverdorben, & Roland E. Kontermann. (2014). Expression and Purification of Recombinant Antibody Formats and Antibody Fusion Proteins. Methods in molecular biology. 1131. 273–295. 8 indexed citations
19.
Seifert, Oliver, et al.. (2013). Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties. Molecular Cancer Therapeutics. 13(1). 101–111. 35 indexed citations
20.
Siegemund, Martin, Nadine Pollak, Oliver Seifert, et al.. (2012). Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death and Disease. 3(4). e295–e295. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mahdi Habibi‐Anbouhi Breakdown of academic impact, for papers by Patrick Bühler Breakdown of academic impact, for papers by Yanchun Meng Breakdown of academic impact, for papers by Elliot C. Woods Breakdown of academic impact, for papers by Patricia Álamo Breakdown of academic impact, for papers by Andrey S. Dobroff Breakdown of academic impact, for papers by Johan Nilvebrant Breakdown of academic impact, for papers by Marta M. Kijanka Breakdown of academic impact, for papers by Martin Hülsmeyer
Rankless by CCL
2026